Genomic-based diagnosis of arrhythmia disease in a personalized medicine era

Abdullah Omar, Mi Zhou, Adam Eric Berman, Robert A Sorrentino, Neela Yar, Neal Lee Weintraub, Il-man Kim, Wei Lei, Yao Liang Tang

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Introduction: Although thousands of potentially disease-causing mutations have been identified in a handful of genes, the genetic heterogeneity has led to diagnostic confusions, stemming directly from the limitations in our arsenal of genetic tools. Areas covered: We discuss the genetic basis of cardiac ion channelopathies, the gaps in our knowledge and how Next-generation sequencing technology (NGS) and can be used to bridge them, and how induced pluripotent stem cell (iPSC) derived-cardiomyocytes can be used for drug discovery. Expert commentary: Univariate, arrhythmogenic arrhythmias can explain some congenital arrhythmias, however, it is far from a comprehensive understanding of the complexity of many arrhythmias. Mutational screening is a critical step in personalized medicine and is critical to the management of patients with arrhythmias. The success of personalized medicine requires a more efficient way to identify a high number of genetic variants potentially implicated in cardiac arrhythmogenic diseases than traditional sequencing methods (eg, Sanger sequencing). Next-generation sequencing technology provides us with unprecedented opportunities to achieve high-throughput, rapid, and cost-effective detection of congenital arrhythmias in patients. Moreover, in personalized medicine era, IPSC derived-cardiomyocytes can be used as ‘cardiac arrhythmia in a dish’ model for drug discovery, and help us improve management of arrhythmias in patients by developing patient-specific drug therapies with target specificity.

Original languageEnglish (US)
Pages (from-to)497-504
Number of pages8
JournalExpert Review of Precision Medicine and Drug Development
Volume1
Issue number6
DOIs
StatePublished - Nov 1 2016

Fingerprint

Precision Medicine
Cardiac Arrhythmias
Drug Discovery
Cardiac Myocytes
Channelopathies
Technology
Induced Pluripotent Stem Cells
Genetic Heterogeneity
Heart Diseases
Ions
Costs and Cost Analysis
Drug Therapy
Mutation
Genes

Keywords

  • Acquired Long QT syndrome
  • Brugada Syndrome
  • Cardiac arrhythmia
  • Catecholaminergic Polymorphic Ventricular Tachycardia
  • Long QT Syndrome
  • Next generation sequencing
  • Personalized Medicine
  • Precision Medicine
  • Short QT syndrome

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Genomic-based diagnosis of arrhythmia disease in a personalized medicine era. / Omar, Abdullah; Zhou, Mi; Berman, Adam Eric; Sorrentino, Robert A; Yar, Neela; Weintraub, Neal Lee; Kim, Il-man; Lei, Wei; Tang, Yao Liang.

In: Expert Review of Precision Medicine and Drug Development, Vol. 1, No. 6, 01.11.2016, p. 497-504.

Research output: Contribution to journalReview article

@article{27f19b562a8b4081ac6be38e1cdd83a6,
title = "Genomic-based diagnosis of arrhythmia disease in a personalized medicine era",
abstract = "Introduction: Although thousands of potentially disease-causing mutations have been identified in a handful of genes, the genetic heterogeneity has led to diagnostic confusions, stemming directly from the limitations in our arsenal of genetic tools. Areas covered: We discuss the genetic basis of cardiac ion channelopathies, the gaps in our knowledge and how Next-generation sequencing technology (NGS) and can be used to bridge them, and how induced pluripotent stem cell (iPSC) derived-cardiomyocytes can be used for drug discovery. Expert commentary: Univariate, arrhythmogenic arrhythmias can explain some congenital arrhythmias, however, it is far from a comprehensive understanding of the complexity of many arrhythmias. Mutational screening is a critical step in personalized medicine and is critical to the management of patients with arrhythmias. The success of personalized medicine requires a more efficient way to identify a high number of genetic variants potentially implicated in cardiac arrhythmogenic diseases than traditional sequencing methods (eg, Sanger sequencing). Next-generation sequencing technology provides us with unprecedented opportunities to achieve high-throughput, rapid, and cost-effective detection of congenital arrhythmias in patients. Moreover, in personalized medicine era, IPSC derived-cardiomyocytes can be used as ‘cardiac arrhythmia in a dish’ model for drug discovery, and help us improve management of arrhythmias in patients by developing patient-specific drug therapies with target specificity.",
keywords = "Acquired Long QT syndrome, Brugada Syndrome, Cardiac arrhythmia, Catecholaminergic Polymorphic Ventricular Tachycardia, Long QT Syndrome, Next generation sequencing, Personalized Medicine, Precision Medicine, Short QT syndrome",
author = "Abdullah Omar and Mi Zhou and Berman, {Adam Eric} and Sorrentino, {Robert A} and Neela Yar and Weintraub, {Neal Lee} and Il-man Kim and Wei Lei and Tang, {Yao Liang}",
year = "2016",
month = "11",
day = "1",
doi = "10.1080/23808993.2016.1264258",
language = "English (US)",
volume = "1",
pages = "497--504",
journal = "Expert Review of Precision Medicine and Drug Development",
issn = "2380-8993",
publisher = "Taylor and Francis Ltd.",
number = "6",

}

TY - JOUR

T1 - Genomic-based diagnosis of arrhythmia disease in a personalized medicine era

AU - Omar, Abdullah

AU - Zhou, Mi

AU - Berman, Adam Eric

AU - Sorrentino, Robert A

AU - Yar, Neela

AU - Weintraub, Neal Lee

AU - Kim, Il-man

AU - Lei, Wei

AU - Tang, Yao Liang

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Introduction: Although thousands of potentially disease-causing mutations have been identified in a handful of genes, the genetic heterogeneity has led to diagnostic confusions, stemming directly from the limitations in our arsenal of genetic tools. Areas covered: We discuss the genetic basis of cardiac ion channelopathies, the gaps in our knowledge and how Next-generation sequencing technology (NGS) and can be used to bridge them, and how induced pluripotent stem cell (iPSC) derived-cardiomyocytes can be used for drug discovery. Expert commentary: Univariate, arrhythmogenic arrhythmias can explain some congenital arrhythmias, however, it is far from a comprehensive understanding of the complexity of many arrhythmias. Mutational screening is a critical step in personalized medicine and is critical to the management of patients with arrhythmias. The success of personalized medicine requires a more efficient way to identify a high number of genetic variants potentially implicated in cardiac arrhythmogenic diseases than traditional sequencing methods (eg, Sanger sequencing). Next-generation sequencing technology provides us with unprecedented opportunities to achieve high-throughput, rapid, and cost-effective detection of congenital arrhythmias in patients. Moreover, in personalized medicine era, IPSC derived-cardiomyocytes can be used as ‘cardiac arrhythmia in a dish’ model for drug discovery, and help us improve management of arrhythmias in patients by developing patient-specific drug therapies with target specificity.

AB - Introduction: Although thousands of potentially disease-causing mutations have been identified in a handful of genes, the genetic heterogeneity has led to diagnostic confusions, stemming directly from the limitations in our arsenal of genetic tools. Areas covered: We discuss the genetic basis of cardiac ion channelopathies, the gaps in our knowledge and how Next-generation sequencing technology (NGS) and can be used to bridge them, and how induced pluripotent stem cell (iPSC) derived-cardiomyocytes can be used for drug discovery. Expert commentary: Univariate, arrhythmogenic arrhythmias can explain some congenital arrhythmias, however, it is far from a comprehensive understanding of the complexity of many arrhythmias. Mutational screening is a critical step in personalized medicine and is critical to the management of patients with arrhythmias. The success of personalized medicine requires a more efficient way to identify a high number of genetic variants potentially implicated in cardiac arrhythmogenic diseases than traditional sequencing methods (eg, Sanger sequencing). Next-generation sequencing technology provides us with unprecedented opportunities to achieve high-throughput, rapid, and cost-effective detection of congenital arrhythmias in patients. Moreover, in personalized medicine era, IPSC derived-cardiomyocytes can be used as ‘cardiac arrhythmia in a dish’ model for drug discovery, and help us improve management of arrhythmias in patients by developing patient-specific drug therapies with target specificity.

KW - Acquired Long QT syndrome

KW - Brugada Syndrome

KW - Cardiac arrhythmia

KW - Catecholaminergic Polymorphic Ventricular Tachycardia

KW - Long QT Syndrome

KW - Next generation sequencing

KW - Personalized Medicine

KW - Precision Medicine

KW - Short QT syndrome

UR - http://www.scopus.com/inward/record.url?scp=85041474641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041474641&partnerID=8YFLogxK

U2 - 10.1080/23808993.2016.1264258

DO - 10.1080/23808993.2016.1264258

M3 - Review article

VL - 1

SP - 497

EP - 504

JO - Expert Review of Precision Medicine and Drug Development

JF - Expert Review of Precision Medicine and Drug Development

SN - 2380-8993

IS - 6

ER -